In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with polycythemia vera, which was presented at the ASH Annual Meeting and Exposition.

John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the ...

In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

This panel was moderated by Ryan McDonald and featured Dr. Jamile Shammo, from Northwestern Medicine, and Dr. John Mascarenhas, from Mount Sinai, who answered questions about polycythemia vera (PV).

Since his diagnosis, Todd has formed a strong, unique partnership with his physician, Dr. John Mascarenhas, a leading hematology-oncology and MPN expert in New York City. Recalling their first ...

Dr. John Mascarenhas discusses the progress of the research around myeloproliferative neoplasms , as well as what more efforts are still needed. This video features Kerry Fraser, a retired NHL referee ...

John Mascarenhas, MD Professor of Medicine, Director, Adult Leukemia Program, Icahn School of Medicine at Mount Sinai, New York, NY Disclosure: John Mascarenhas, MD, has disclosed the following ...

About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or ...

Dr. Mascarenhas believes that despite recent advances in immunomodulatory treatment, an unmet need still exists for therapeutic strategies to prevent disease progression in hospitalized patients.